30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Pyxis Oncology Inc (PYXS)

Track

The most recent insider trading activity occurred on April 21, 2025, with Director Rachel Humphrey executing planned and proposed sales totaling approximately $28,723. Prior to this, on November 26, 2024, CFO & COO Pamela Ann Connealy made purchases valued at approximately $174,364. Earlier transactions in September 2023 also show buying activity from Ms. Connealy and Chief Accounting Officer Jitendra Wadhane.
Stock chart
Ticker: PYXS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
HUMPHREY RACHEL
2 sales — total 28,723 USD
Planned sale 21 Apr 2025
Value US$3,722,616.34 | Price 95.46 | Shares 25,142
Proposed sale 21 Apr 2025
Value US$120,783.83 | Price 473.43 | Shares 45,473
Planned sale 17 Apr 2025
Value US$1,649,776.67 | Price 368.83 | Shares 57,021
Proposed sale 17 Apr 2025
Value US$962,393.07 | Price 386.39 | Shares 60,693
Planned sale 14 Apr 2025
Value US$1,361.78 | Price 0.97 | Shares 1,400
Proposed sale 14 Apr 2025
Value US$1,361.96 | Price 0.97 | Shares 1,400
Buy 26 Nov 2024
Value US$163,464.00 | Price 1.96 | Shares 83,400
Buy 26 Nov 2024
Value US$10,900.00 | Price 2.00 | Shares 5,450
Buy 28 Sep 2023
Value US$14,960.00 | Price 1.87 | Shares 8,000
Buy 27 Sep 2023
Value US$11,867.54 | Price 1.85 | Shares 6,426
Buy 27 Sep 2023
Value US$4,675.00 | Price 1.87 | Shares 2,500
Buy 25 Sep 2023
Value US$8,850.00 | Price 1.77 | Shares 5,000
Buy 25 Sep 2023
Value US$20,043.60 | Price 1.67 | Shares 12,000
Buy 22 Sep 2023
Value US$8,695.00 | Price 1.74 | Shares 5,000
Buy 22 Sep 2023
Value US$4,349.25 | Price 1.74 | Shares 2,500
Proposed sale 18 Sep 2023
Value US$17,936.10 | Price 2.10 | Shares 8,541
Sale 18 Sep 2023
Value US$17,936.10 | Price 2.10 | Shares 8,541
Sale 14 Sep 2023
Value US$225.00 | Price 2.25 | Shares 100
Proposed sale 14 Sep 2023
Value US$225.00 | Price 2.25 | Shares 100
Proposed sale 13 Sep 2023
Value US$6,815.82 | Price 2.27 | Shares 3,000
Sale 13 Sep 2023
Value US$6,815.70 | Price 2.27 | Shares 3,000
Sale 12 Sep 2023
Value US$11,071.12 | Price 2.25 | Shares 4,917
Proposed sale 12 Sep 2023
Value US$11,070.95 | Price 2.25 | Shares 4,917
Sale 11 Sep 2023
Value US$45,414.00 | Price 2.27 | Shares 20,000
Proposed sale 11 Sep 2023
Value US$45,414.04 | Price 2.27 | Shares 20,000
Proposed sale 5 Sep 2023
Value US$42,918.80 | Price 2.37 | Shares 18,109
Proposed sale 11 Aug 2023
Value US$126,480.58 | Price 2.53 | Shares 50,000
Proposed sale 1 Aug 2023
Value US$63,070.50 | Price 2.52 | Shares 25,000
Proposed sale 31 Jul 2023
Value US$64,604.83 | Price 2.58 | Shares 25,000
Proposed sale 27 Jul 2023
Value US$56,008.69 | Price 2.43 | Shares 23,021
Proposed sale 27 Jul 2023
Value US$56,008.69 | Price 2.43 | Shares 23,021
Proposed sale 21 Jul 2023
Value US$71,380.21 | Price 2.61 | Shares 27,361
Proposed sale 11 Jul 2023
Value US$83,059.44 | Price 2.77 | Shares 30,000
Proposed sale 16 Jun 2023
Value US$694.63 | Price 2.97 | Shares 234
Proposed sale 8 Jun 2023
Value US$71,107.19 | Price 3.01 | Shares 23,637
Proposed sale 7 Jun 2023
Value US$116,727.90 | Price 3.12 | Shares 37,402
Buy 17 Mar 2023
Value US$4,999,999.44 | Price 2.76 | Shares 1,811,594
Sale 21 Apr 2022
Value US$5,324,571.05 | Price 3.05 | Shares 1,745,761
Buy 8 Dec 2021
Value US$93,885.00 | Price 9.39 | Shares 10,000
Buy 18 Nov 2021
Value US$200,018.00 | Price 12.74 | Shares 15,700
Buy 13 Oct 2021
Value US$5,000,000.00 | Price 16.00 | Shares 312,500
Buy 13 Oct 2021
Value US$7,200,000.00 | Price 16.00 | Shares 450,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-25 2025-04-21 PlS Planned sale
HUMPHREY RACHEL
Non-Executive Director
25,142 +18.5%
95.46
US$3,722,616 		25,142 +18.5% 95.46 US$3,722,616
2025-04-21 2025-04-21 PrS Proposed sale
HUMPHREY RACHEL

Director

Non-Executive Director
45,473
473.43
US$120,784 		45,473 473.43 US$120,784
2026-03-25 2025-04-17 PlS Planned sale
HUMPHREY RACHEL
Non-Executive Director
57,021 -5.7%
368.83
US$1,649,777 		57,021 -5.7% 368.83 US$1,649,777
2025-04-17 2025-04-17 PrS Proposed sale
HUMPHREY RACHEL

Director

Non-Executive Director
200
0.97
US$194 		200 0.97 US$194
2026-03-25 2025-04-14 PlS Planned sale
HUMPHREY RACHEL
Non-Executive Director
1,400 -1.4%
0.97
US$1,362 		1,400 -1.4% 0.97 US$1,362
2025-04-14 2025-04-14 PrS Proposed sale
HUMPHREY RACHEL

Director

Non-Executive Director
1,400
0.97
US$1,362 		1,400 0.97 US$1,362
2024-11-27 2024-11-26 B Purchase
1.5
Connealy Pamela Ann

CFO & COO

Officer
83,400 +7.5%
1.96
US$163,464 		83,400 +7.5% 1.96 US$163,464
2024-11-27 2024-11-26 B Purchase
1.5
Connealy Pamela Ann

CFO & COO

Officer
5,450 +0.5%
2.00
US$10,900 		5,450 +0.5% 2.00 US$10,900
2023-09-28 2023-09-28 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
8,000 +1.0%
1.87
US$14,960 		8,000 +1.0% 1.87 US$14,960
2023-09-27 2023-09-27 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
6,426 +0.8%
1.85
US$11,868 		6,426 +0.8% 1.85 US$11,868
2023-09-27 2023-09-27 B Purchase
2.0
Wadhane Jitendra

Chief Accounting Officer

Officer
2,500 +1.1%
1.87
US$4,675 		2,500 +1.1% 1.87 US$4,675
2023-09-25 2023-09-25 B Purchase
2.0
Wadhane Jitendra

Chief Accounting Officer

Officer
5,000 +2.3%
1.77
US$8,850 		5,000 +2.3% 1.77 US$8,850
2023-09-25 2023-09-25 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
12,000 +1.5%
1.67
US$20,044 		12,000 +1.5% 1.67 US$20,044
2023-09-22 2023-09-22 B Purchase
1.5
Connealy Pamela Ann

CFO and COO

Officer
5,000 +0.6%
1.74
US$8,695 		5,000 +0.6% 1.74 US$8,695
2023-09-22 2023-09-22 B Purchase
2.0
Wadhane Jitendra

Chief Accounting Officer

Officer
2,500 +1.2%
1.74
US$4,349 		2,500 +1.2% 1.74 US$4,349
2023-09-18 2023-09-18 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
8,541
2.10
US$17,936 		8,541 2.10 US$17,936
2023-09-18 2023-09-18 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
8,541 -0.4%
2.10
US$17,936 		8,541 -0.4% 2.10 US$17,936
2023-09-18 2023-09-14 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
100 -0.0%
2.25
US$225 		100 -0.0% 2.25 US$225
2023-09-14 2023-09-14 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
100
2.25
US$225 		100 2.25 US$225
2023-09-13 2023-09-13 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
3,000
2.27
US$6,816 		3,000 2.27 US$6,816
2023-09-13 2023-09-13 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
3,000 -0.1%
2.27
US$6,816 		3,000 -0.1% 2.27 US$6,816
2023-09-13 2023-09-12 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
4,917 -0.2%
2.25
US$11,071 		4,917 -0.2% 2.25 US$11,071
2023-09-12 2023-09-12 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
4,917
2.25
US$11,071 		4,917 2.25 US$11,071
2023-09-13 2023-09-11 S Sale
3.1
Sullivan Lara

President and CEO

Executive Director
20,000 -0.8%
2.27
US$45,414 		20,000 -0.8% 2.27 US$45,414
2023-09-11 2023-09-11 PrS Proposed sale
3.1
Sullivan Lara

Officer; Director

Executive Director
20,000
2.27
US$45,414 		20,000 2.27 US$45,414
2023-09-05 2023-09-05 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
18,109
2.37
US$42,919 		18,109 2.37 US$42,919
2023-08-11 2023-08-11 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
50,000
2.53
US$126,481 		50,000 2.53 US$126,481
2023-08-01 2023-08-01 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
25,000
2.52
US$63,070 		25,000 2.52 US$63,070
2023-07-31 2023-07-31 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
25,000
2.58
US$64,605 		25,000 2.58 US$64,605
2023-07-28 2023-07-27 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
23,021
2.43
US$56,009 		23,021 2.43 US$56,009
2023-07-27 2023-07-27 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
23,021
2.43
US$56,009 		23,021 2.43 US$56,009
2023-07-21 2023-07-21 PrS Proposed sale
Feingold Jay

Former Chief Medical Officer

Officer
27,361
2.61
US$71,380 		27,361 2.61 US$71,380
2023-07-11 2023-07-11 PrS Proposed sale
Feingold Jay

Former Officer

Officer
30,000
2.77
US$83,059 		30,000 2.77 US$83,059
2023-06-16 2023-06-16 PrS Proposed sale
Feingold Jay

Officer

Officer
234
2.97
US$695 		234 2.97 US$695
2023-06-08 2023-06-08 PrS Proposed sale
Feingold Jay

Officer

Officer
23,637
3.01
US$71,107 		23,637 3.01 US$71,107
2023-06-07 2023-06-07 PrS Proposed sale
Feingold Jay

Officer

Officer
37,402
3.12
US$116,728 		37,402 3.12 US$116,728
2023-03-21 2023-03-17 B Purchase
3.4
PFIZER INC
Large shareholder
1,811,594 +43.8%
2.76
US$4,999,999 		1,811,594 +43.8% 2.76 US$4,999,999
2022-04-25 2022-04-21 S Sale
2.8
Chin Mark

Former Director
1,745,761 -100.0%
3.05
US$5,324,571 		1,745,761 -100.0% 3.05 US$5,324,571
2021-12-09 2021-12-08 B Purchase
1.3
Cline Darren S
Non-Executive Director
10,000 +inf%
9.39
US$93,885 		10,000 +inf% 9.39 US$93,885
2021-11-19 2021-11-18 B Purchase
0.8
Civik Thomas
Non-Executive Director
15,700 +inf%
12.74
US$200,018 		15,700 +inf% 12.74 US$200,018
2021-10-15 2021-10-13 B Purchase
2.8
Chin Mark
Non-Executive Director
312,500 +21.8%
16.00
US$5,000,000 		312,500 +21.8% 16.00 US$5,000,000
2021-10-15 2021-10-13 B Purchase
3.8
Cormorant Asset Management, LP
450,000 +67.3%
16.00
US$7,200,000 		450,000 +67.3% 16.00 US$7,200,000
Explore more

More insider trading research around Pyxis Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America